Latest News in the pharma Industry

Research & Development

GSK receives positive CHMP opinion in Europe for Strimvelis, the first gene therapy to treat very rare disease, ADA-SCID

GSK receives positive CHMP opinion in Europe for Strimvelis, the first gene therapy to treat very rare disease, ADA-SCID

4 Apr 2016

The medicine is a stem cell gene therapy created for an individual patient from their own cells which is intended to correct the root cause of the disease.

Read more 
RedHill Biopharma's interim results from Phase IIa PoC study supporting therapeutic potential of RHB-104 in multiple sclerosis

RedHill Biopharma's interim results from Phase IIa PoC study supporting therapeutic potential of RHB-104 in multiple sclerosis

4 Apr 2016

RedHill Biopharma's interim results from Phase IIa proof-of-concept study supporting therapeutic potential of RHB-104 in multiple sclerosis

Read more 
Janssen receives CHMP Positive Opinion for Trevicta recommending approval in EU for maintenance treatment of schizophrenia

Janssen receives CHMP Positive Opinion for Trevicta recommending approval in EU for maintenance treatment of schizophrenia

3 Apr 2016

If approved, Trevica will be the first treatment for schizophrenia to be administered four times a year and will provide the longest dosing interval available for an antipsychotic medication in the EU.

Read more 
Flixabi, an infliximab biosimilar candidate referencing Remicade, receives positive CHMP opinion

Flixabi, an infliximab biosimilar candidate referencing Remicade, receives positive CHMP opinion

2 Apr 2016

Flixabi to be the second anti-TNF biosimilar commercialized and manufactured by Biogen in the EU.

Read more 
Phase III study findings demonstrate treatment with baricitinib results in significant improvements for patients with RA who had inadequate response to biologics

Phase III study findings demonstrate treatment with baricitinib results in significant improvements for patients with RA who had inadequate response to biologics

31 Mar 2016

Pivotal RA-BEACON study published in New England Journal of Medicine.

Read more 
EMA Validates BMS application for Opdivo for the treatment of classical Hodgkin lymphoma patients

EMA Validates BMS application for Opdivo for the treatment of classical Hodgkin lymphoma patients

31 Mar 2016

Opdivo has potential to become first PD-1 inhibitor approved in a hematological malignancy in European Union.

Read more 
SIR-Spheres Y-90 resin microspheres are a well-tolerated alternative to standard therapies for inoperable primary liver cancer, says new UK NICE MIB

SIR-Spheres Y-90 resin microspheres are a well-tolerated alternative to standard therapies for inoperable primary liver cancer, says new UK NICE MIB

31 Mar 2016

Unlike TACE, most patients treated with SIR-Spheres Y-90 resin microspheres usually require only a single treatment.

Read more 
SGS and DiscoverX to collaborate on the qualification and supply of bioassays for biopharmaceutical development

SGS and DiscoverX to collaborate on the qualification and supply of bioassays for biopharmaceutical development

30 Mar 2016

The availability of commercial ready-to-assay cryopreserved cells in a qualified kit will remove the need for developers to employ challenging and time-consuming method development procedures.

Read more 
BMS and Pfizer announce global real-world data program and present new analyses of Eliquis at the American College of Cardiology’s 65th Annual Scientific Session

BMS and Pfizer announce global real-world data program and present new analyses of Eliquis at the American College of Cardiology’s 65th Annual Scientific Session

30 Mar 2016

Seventeen abstracts to be presented, including new analyses from the Phase III ARISTOTLE and AMPLIFY clinical studies and from real-world databases.

Read more 
Microneedle patch delivers localized cancer immunotherapy to melanoma

Microneedle patch delivers localized cancer immunotherapy to melanoma

29 Mar 2016

Researchers developed a patch that uses microneedles to deliver anti-PD-1 antibodies locally to the skin tumour.

Read more 
EMA accepts for review Pfizer's MAA for Xeljanz for the treatment of moderate to severe rheumatoid arthritis

EMA accepts for review Pfizer's MAA for Xeljanz for the treatment of moderate to severe rheumatoid arthritis

28 Mar 2016

Application provides additional information to the original MAA submission, including data from the Phase III ORAL global development program in RA.

Read more 
Regeneron and Bayer to jointly develop novel combination therapy for eye diseases

Regeneron and Bayer to jointly develop novel combination therapy for eye diseases

24 Mar 2016

Will jointly develop a combination therapy of the angiopoietin2 (Ang2) antibody nesvacumab and the vascular endothelial growth factor (VEGF) trap aflibercept, for the treatment of serious eye diseases.

Read more